AbbVie Submits Applications To FDA And EMA For New Indication Of Upadacitinib (RINVOQ) For Treatment Of Giant Cell Arteritis; Supported By Phase 3 SELECT-GCA Study Showing Sustained Remission And Consistent Safety Profile
AbbVie Submits Applications To FDA And EMA For New Indication Of Upadacitinib (RINVOQ) For Treatment Of Giant Cell Arteritis; Supported By Phase 3 SELECT-GCA Study Showing Sustained Remission And Consistent Safety Profile
艾伯維公司向FDA和EMA提交新應用申請，用於治療鉅細胞動脈炎的Upadacitinib（RINVOQ）；SELECt-GCA III期研究顯示持續緩解和一致的安全性。
AbbVie Submits Applications To FDA And EMA For New Indication Of Upadacitinib (RINVOQ) For Treatment Of Giant Cell Arteritis; Supported By Phase 3 SELECT-GCA Study Showing Sustained Remission And Consistent Safety Profile
艾伯維公司向FDA和EMA提交新應用申請，用於治療鉅細胞動脈炎的Upadacitinib（RINVOQ）；SELECt-GCA III期研究顯示持續緩解和一致的安全性。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。